No difference seen in 28-day mortality or occurrence of serious adverse events; time to resolution of ACLF significantly faster <\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, June 2, 2023 (HealthDay News) — The DIALIVE novel liver dialysis device seems safe and has a positive impact for patients with acute-on-chronic liver failure (ACLF), according to a study published online May 31 in the Journal of Hepatology<\/em>.<\/p>\n Banwari Agarwal, M.B.B.S., M.D., from the Royal Free Hospital in London, and colleagues examined the safety of DIALIVE in 32 patients with alcohol-related ACLF compared to standard of care (17 with DIALIVE; 15 with standard of care). In the randomized trial, DIALIVE patients were treated for up to five days; at day 10, end points were assessed.<\/p>\n The researchers found that 28-day mortality and occurrence of serious adverse events did not differ significantly between the groups. The DIALIVE group had a significant reduction in the severity of endotoxemia and improvement in albumin function, which translated to a significant reduction in the Chronic Liver Failure consortium (CLIF-C) organ failure and CLIF-C ACLF scores at day 10. The DIALIVE group had significantly faster time to resolution of ACLF. Significant improvement in biomarkers of systemic inflammation, including interleukin-8, cell death, endothelial function, and ligands for Toll-like receptor 4 and inflammasome, was seen in the DIALIVE group.<\/p>\n “These data indicate that DIALIVE may be a disease-modifying therapy for ACLF patients and could impact the outcome of patients with ACLF, for which there is no available therapy except liver transplantation available to a very small minority of these patients,” a coauthor said in a statement. “The potential impact is huge if these data can be confirmed in larger clinical trials.”<\/p>\n Several authors disclosed ties to biotechnology and medical technology companies, including Yaqrit Discovery, which holds the intellectual property for DIALIVE.<\/p>\n